{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:39:16Z","timestamp":1786563556487,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","funder":[{"name":"Biogen, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40120-015-0033-1","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T04:46:16Z","timestamp":1444711576000},"page":"93-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience"],"prefix":"10.1007","volume":"4","author":[{"given":"Ralf","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Theodore","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Havrdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bar-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Thullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Novas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne T.","family":"Sweetser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuwan","family":"Kurukulasuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vissia","family":"Viglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"33_CR1","first-page":"S15","volume":"19","author":"MJ Tullman","year":"2013","unstructured":"Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19:S15\u201320.","journal-title":"Am J Manag Care."},{"key":"33_CR2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40263-013-0131-5","volume":"28","author":"E Lu","year":"2014","unstructured":"Lu E, Wang BW, Synnes A, Dahlgren L, Sadovnick AD, Tremlett H. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs. 2014;28:89\u201394.","journal-title":"CNS Drugs."},{"issue":"3","key":"33_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1586\/ern.13.12","volume":"13","author":"E Lu","year":"2013","unstructured":"Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013;13(3):251\u201361.","journal-title":"Expert Rev Neurother"},{"key":"33_CR4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1191\/1352458504ms1083oa","volume":"10","author":"PK Coyle","year":"2004","unstructured":"Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler. 2004;10:582\u20138.","journal-title":"Mult Scler."},{"key":"33_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/01.wnl.0000438222.17976.b2","volume":"82","author":"AM Langer-Gould","year":"2014","unstructured":"Langer-Gould AM. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014;82:1\u20132.","journal-title":"Neurology."},{"key":"33_CR6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clineuro.2012.04.024","volume":"115","author":"YD Fragoso","year":"2013","unstructured":"Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2013;115:154\u20139.","journal-title":"Clin Neurol Neurosurg"},{"key":"33_CR7","unstructured":"Tecfidera (dimethyl fumarate) prescribing information. Cambridge: Biogen Inc.; 2013. http:\/\/www.tecfidera.com\/pdfs\/full-prescribing-information.pdf . Accessed Oct 21, 2014."},{"key":"33_CR8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"RA Linker","year":"2011","unstructured":"Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678\u201392.","journal-title":"Brain."},{"key":"33_CR9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","volume":"341","author":"RH Scannevin","year":"2012","unstructured":"Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341:274\u201384.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"33_CR10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"12","key":"33_CR11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips T, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"key":"33_CR12","unstructured":"International Conference on Harmonisation [ICH] S5(R2) guideline: Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility, current Step 4 version. 2005."},{"issue":"1","key":"33_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0890-6238(98)00060-4","volume":"13","author":"I Chahoud","year":"1999","unstructured":"Chahoud I, Buschmann J, Clark R, et al. Classification terms in developmental toxicology: need for harmonization. Report of the second workshop on the terminology in developmental toxicology. Reprod Toxicol. 1999;13(1):77\u201382.","journal-title":"Reprod Toxicol"},{"key":"33_CR14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1590\/S0100-879X2005000400010","volume":"38","author":"I Chahoud","year":"2005","unstructured":"Chahoud I, Paumgartten FJR. Relationships between fetal body weight of Wistar rats at term and the extent of skeletal ossification. Braz J Med Biol Res. 2005;38:565\u201375.","journal-title":"Braz J Med Biol Res"},{"issue":"6","key":"33_CR15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/bdrb.20133","volume":"80","author":"EW Carney","year":"2007","unstructured":"Carney EW, Kimmel CA. Interpretation of skeletal variations for human risk assessment: delayed ossification and wavy ribs. Birth Defects Res B Dev Reprod Toxicol. 2007;80(6):473\u201396.","journal-title":"Birth Defects Res B Dev Reprod Toxicol."},{"issue":"3","key":"33_CR16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0300-483X(81)90088-3","volume":"22","author":"T Matsuzawa","year":"1981","unstructured":"Matsuzawa T, Nakata M, Goto I, Tsushima M. Dietary deprivation induces fetal loss and abortion in rabbits. Toxicology. 1981;22(3):255\u20139.","journal-title":"Toxicology"},{"issue":"3","key":"33_CR17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0272-0590(91)90208-L","volume":"17","author":"RL Clark","year":"1991","unstructured":"Clark RL, Antonello JM, Wenger JD, Deverle-Brooks K, Duchai DM. Selection of food allotment for New Zealand white rabbits in developmental toxicity studies. Fundam Appl Toxicol. 1991;17(3):584\u201392.","journal-title":"Fundam Appl Toxicol"},{"issue":"2","key":"33_CR18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2131\/jts.31.169","volume":"31","author":"T Matsuoka","year":"2006","unstructured":"Matsuoka T, Mizoguchi Y, Serizawa K, Ishikura T, Mizuguchi H, Asano Y. Effects of stage and degree of restricted feeding on pregnancy outcome in rabbits. J Toxicol Sci. 2006;31(2):169\u201375.","journal-title":"J Toxicol Sci"},{"key":"33_CR19","unstructured":"Cappon GD, Fleeman TL, Chapin RE, Hurtt ME. Effects of feed restriction during organogenesis on embryo-fetal development in rabbit. BDR(B). 2006;74:424\u201330."},{"issue":"7","key":"33_CR20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/096032719501400703","volume":"14","author":"DE Prentice","year":"1995","unstructured":"Prentice DE, Meikle AW. A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Hum Exp Toxicol. 1995;14(7):562\u201372.","journal-title":"Hum Exp Toxicol"},{"issue":"2","key":"33_CR21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/10408449991349203","volume":"29","author":"JC Cook","year":"1999","unstructured":"Cook JC, Klinefelter GR, Hardisty JF, Sharpe RM, Foster PM. Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit Rev Toxicol. 1999;29(2):169\u2013261.","journal-title":"Crit Rev Toxicol"},{"issue":"1","key":"33_CR22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0890-6238(96)00203-1","volume":"11","author":"ED Clegg","year":"1997","unstructured":"Clegg ED, Cook JC, Chapin RE, Foster PM, Daston GP. Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Reprod Toxicol. 1997;11(1):107\u201321.","journal-title":"Reprod Toxicol"},{"issue":"2","key":"33_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.jp.7210614","volume":"22","author":"W Zaw","year":"2002","unstructured":"Zaw W, Stone DG. Caudal regression syndrome in twin pregnancy with type II diabetes. J Perinatol. 2002;22(2):171\u20134.","journal-title":"J Perinatol"},{"key":"33_CR24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2210-4-22","volume":"4","author":"NH Litjens","year":"2004","unstructured":"Litjens NH, van Strijen E, van Gulpen C, et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 2004;4:22. doi: 10.1186\/1471-2210-4-22 .","journal-title":"BMC Pharmacol"},{"issue":"2","key":"33_CR25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0301-2115(01)00613-3","volume":"102","author":"A Garc\u00eda-Engu\u00eddanos","year":"2002","unstructured":"Garc\u00eda-Engu\u00eddanos A, Calle ME, Valero J, Luna S, Dom\u00ednguez-Rojas V. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol. 2002;102(2):111\u20139.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"33_CR26","unstructured":"Gilenya (fingolimod) prescribing information. East Hanover: Novartis International AG; 2014. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdf . Accessed Oct 21, 2014."},{"key":"33_CR27","unstructured":"Aubagio (teriflunomide) prescribing information. Cambridge: Genzyme Corporation, a Sanofi company; 2012. http:\/\/products.sanofi.us\/aubagio\/aubagio.pdf . Accessed Oct 21, 2014."},{"key":"33_CR28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","volume":"82","author":"G Karlsson","year":"2014","unstructured":"Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674\u201380.","journal-title":"Neurology."},{"key":"33_CR29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1352458509106543","volume":"15","author":"C Weber-Schoendorfer","year":"2009","unstructured":"Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009;15:1037\u201342.","journal-title":"Mult Scler."},{"key":"33_CR30","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1212\/WNL.0b013e3181fd62bb","volume":"75","author":"MP Amato","year":"2010","unstructured":"Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-\u03b2 exposure in multiple sclerosis. Neurology. 2010;75:1794\u2013802.","journal-title":"Neurology."},{"key":"33_CR31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s00415-012-6653-9","volume":"260","author":"MK Houtchens","year":"2013","unstructured":"Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2013;260:1202\u201314.","journal-title":"J Neurol"},{"issue":"6","key":"33_CR32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00415-008-0757-2","volume":"255","author":"J Dahl","year":"2008","unstructured":"Dahl J, Myhr KM, Daltveit AK, Gilhus NE. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol. 2008;255(6):623\u20137.","journal-title":"J Neurol"},{"issue":"11","key":"33_CR33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182698c64","volume":"79","author":"E Lu","year":"2012","unstructured":"Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130\u20135.","journal-title":"Neurology."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-015-0033-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T21:08:12Z","timestamp":1498252092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40120-015-0033-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1007\/s40120-015-0033-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,12]]}}}